Literature DB >> 9870211

Cholesterol and oxygenated cholesterol concentrations are markedly elevated in peripheral tissue but not in brain from mice with the Niemann-Pick type C phenotype.

G S Tint1, P Pentchev, G Xu, A K Batta, S Shefer, G Salen, A Honda.   

Abstract

Niemann-Pick disease type C (NP-C) is a rare genetic disorder characterized by progressive neurodegeneration, frequent developmental delay and early death. Tissues of affected individuals accumulate large quantities of free cholesterol in lysosomes. Because cytotoxic oxygenated derivatives of cholesterol are known to form readily when cholesterol concentrations are elevated, we searched for these compounds in liver, kidney, spleen and brain from mice with the NP-C phenotype. In order of abundance, we identified 7 alpha- and 7 beta-hydroxycholesterol, 5 alpha, 6 alpha-epoxycholestan-3 beta-ol, 4 beta-hydroxycholesterol, cholest-4-en-3 beta, 7 alpha-diol and cholest-4-en-3 beta, 6 beta-diol in most tissue samples. Cholesterol concentrations in affected mice were increased 3-fold in kidney and 7- to 8-fold in spleen and liver compared to controls (all p < 0.001) but were unchanged in brain. Although oxysterol levels were markedly elevated in nonbrain tissue, the oxysterol and cholesterol concentrations increased proportionally so that oxysterols expressed as percentage of total sterols were the same for all animals (0.34 +/- 0.19% averaged over all organs in affected animals vs 0.40 +/- 0.42% in control mice). In contrast to peripheral tissue, we could not detect any increase in either absolute or relative oxysterol levels in the brains of affected and control mice (49 +/- 61 vs 53 +/- 43 micrograms/g wet weight and 0.45 +/- 0.52 vs 0.47 +/- 0.37%, respectively). Thus, brain sterols are normal in NP-C mice and it is unlikely that an accumulation of cytotoxic oxygenated derivatives of cholesterol could account for the progressive neuropathology seen in the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870211     DOI: 10.1023/a:1005474803278

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  57 in total

Review 1.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

Review 2.  Role of oxidized low density lipoprotein in atherogenesis.

Authors:  J L Witztum; D Steinberg
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 3.  Biological activities of oxysterols.

Authors:  L L Smith; B H Johnson
Journal:  Free Radic Biol Med       Date:  1989       Impact factor: 7.376

4.  Type C Niemann-Pick disease: documentation of abnormal LDL processing in lymphocytes.

Authors:  C E Argoff; C R Kaneski; E J Blanchette-Mackie; M Comly; N K Dwyer; A Brown; R O Brady; P G Pentchev
Journal:  Biochem Biophys Res Commun       Date:  1990-08-31       Impact factor: 3.575

5.  Identification of regulatory oxysterols, 24(S),25-epoxycholesterol and 25-hydroxycholesterol, in cultured fibroblasts.

Authors:  S E Saucier; A A Kandutsch; F R Taylor; T A Spencer; S Phirwa; A K Gayen
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

6.  Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease.

Authors:  D A Kelly; B Portmann; A P Mowat; S Sherlock; B D Lake
Journal:  J Pediatr       Date:  1993-08       Impact factor: 4.406

7.  Fetal Niemann-Pick disease type C: ultrastructural and lipid findings in liver and spleen.

Authors:  C Dumontel; C Girod; F Dijoud; Y Dumez; M T Vanier
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture.

Authors:  J W Heinecke; H Rosen; A Chait
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

9.  Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages.

Authors:  L M Hultén; H Lindmark; U Diczfalusy; I Björkhem; M Ottosson; Y Liu; G Bondjers; O Wiklund
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

10.  Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages.

Authors:  I Björkhem; O Andersson; U Diczfalusy; B Sevastik; R J Xiu; C Duan; E Lund
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

View more
  21 in total

1.  A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma.

Authors:  Xuntian Jiang; Rohini Sidhu; Forbes D Porter; Nicole M Yanjanin; Anneliese O Speak; Danielle Taylor te Vruchte; Frances M Platt; Hideji Fujiwara; David E Scherrer; Jessie Zhang; Dennis J Dietzen; Jean E Schaffer; Daniel S Ory
Journal:  J Lipid Res       Date:  2011-04-24       Impact factor: 5.922

2.  FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.

Authors:  Jason Newton; Nitai C Hait; Michael Maceyka; Alexandria Colaco; Melissa Maczis; Christopher A Wassif; Antony Cougnoux; Forbes D Porter; Sheldon Milstien; Nicholas Platt; Frances M Platt; Sarah Spiegel
Journal:  FASEB J       Date:  2017-01-12       Impact factor: 5.191

3.  Quantitative Proteomics of Human Fibroblasts with I1061T Mutation in Niemann-Pick C1 (NPC1) Protein Provides Insights into the Disease Pathogenesis.

Authors:  Navin Rauniyar; Kanagaraj Subramanian; Mathieu Lavallée-Adam; Salvador Martínez-Bartolomé; William E Balch; John R Yates
Journal:  Mol Cell Proteomics       Date:  2015-04-14       Impact factor: 5.911

4.  Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease.

Authors:  Forbes D Porter; David E Scherrer; Michael H Lanier; S Joshua Langmade; Vasumathi Molugu; Sarah E Gale; Dana Olzeski; Rohini Sidhu; Dennis J Dietzen; Rao Fu; Christopher A Wassif; Nicole M Yanjanin; Steven P Marso; John House; Charles Vite; Jean E Schaffer; Daniel S Ory
Journal:  Sci Transl Med       Date:  2010-11-03       Impact factor: 17.956

5.  Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice.

Authors:  R P Erickson; W S Garver; F Camargo; G S Hossain; R A Heidenreich
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

6.  Mass spectrometry imaging of lipids: untargeted consensus spectra reveal spatial distributions in Niemann-Pick disease type C1.

Authors:  Fernando Tobias; Matthew T Olson; Stephanie M Cologna
Journal:  J Lipid Res       Date:  2018-09-28       Impact factor: 5.922

7.  Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling.

Authors:  Martin Fan; Rohini Sidhu; Hideji Fujiwara; Brett Tortelli; Jessie Zhang; Cristin Davidson; Steven U Walkley; Jessica H Bagel; Charles Vite; Nicole M Yanjanin; Forbes D Porter; Jean E Schaffer; Daniel S Ory
Journal:  J Lipid Res       Date:  2013-07-23       Impact factor: 5.922

8.  Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport.

Authors:  David E Sleat; Jennifer A Wiseman; Mukarram El-Banna; Sandy M Price; Lucie Verot; Michael M Shen; G Stephen Tint; Marie T Vanier; Steven U Walkley; Peter Lobel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

Review 9.  Diagnostic workup and management of patients with suspected Niemann-Pick type C disease.

Authors:  Apostolos Papandreou; Paul Gissen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

10.  Determination of 7-ketocholesterol in plasma by LC-MS for rapid diagnosis of acid SMase-deficient Niemann-Pick disease.

Authors:  Na Lin; Huiwen Zhang; Wenjuan Qiu; Jun Ye; Lianshu Han; Yu Wang; Xuefan Gu
Journal:  J Lipid Res       Date:  2013-11-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.